复方斑蝥胶囊联合奥沙利铂治疗非小细胞肺癌的疗效观察
|
摘要
目的观察复方斑蝥胶囊联合注射用奥沙利铂治疗非小细胞肺癌的临床疗效。方法选取2015年1月—2017年9月沧州市中心医院收治的80例非小细胞肺癌患者作为研究对象,将所有患者随机分为对照组(36例)和治疗组(44例)。对照组患者静脉输注注射用奥沙利铂,130 mg/m~2加入5%葡萄糖溶液250～500 mL中,输注2～6 h。治疗组患者在对照组治疗的基础上口服复方斑蝥胶囊,3粒/次,2次/d。3周为1个疗程,两组患者连续治疗6个疗程。观察两组患者的临床疗效,比较两组治疗前后的卡氏评分(KPS)和不良反应发生情况。结果治疗后,对照组和治疗组客观缓解率分别为33.33%、56.82%,疾病控制率分别为83.33%、90.91%,两组比较差异无统计学意义。治疗后,两组患者KPS评分均显著升高(P<0.05);且治疗组KPS评分显著高于对照组(P<0.05)。治疗期间,对照组发生口腔黏膜炎、肝肾功能异常和周围神经毒性患者例数显著高于治疗组,两组不良反应发生情况比较差异具有统计学意义(P<0.05)。结论复方斑蝥胶囊联合注射用奥沙利铂治疗非小细胞肺癌具有较好的临床疗效,能够提高患者生活质量,降低药物不良反应,具有一定的临床推广应用价值。
Objective To observe the therapeutic effect of Compound Banmao Capsules combined with Oxaliplatin for injection in treatment of non-small cell lung cancer. Methods Patients(80 cases) with non-small cell lung cancer in Cangzhou Central Hospital from January 2015 to September 2017 were randomly divided into control(36 cases) and treatment(44 cases) groups. Patients in the control group were iv administered with Oxaliplatin for injection, 130 mg/m~2 added into 5% Glucose Solution 250 — 500 mL for 2 —6 h. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of control group, 3 grains/time, twice daily. A course of treatment had 3 weeks, and patients in two groups were treated for 6 courses. After treatment, the clinical effect was evaluated, and the KPS and adverse reactions in two groups before and after treatment were compared. Results After treatment, objective remission rates in the control and treatment groups were 33.33% and 56.82%, and the disease control rates were83.33% and 90.91%, respectively, but there were not statistically significant difference between two groups. After treatment, the KPS in the two groups were significantly increased(P < 0.05). And KPS in the treatment group were higher than that in the control group(P < 0.05). During the treatment, the number of patients with oral mucositis, abnormal liver and kidney function, and peripheral neurotoxicity in the control group were significantly higher than those in the treatment group, and there were differences between two groups(P < 0.05). Conclusion Compound Banmao Capsules combined with Oxaliplatin for injection has good clinical efficacy in the treatment of non-small cell lung cancer, can improve the quality of life of patients, and reduce adverse drug reactions, which has a certain clinical application value.
Objective To observe the therapeutic effect of Compound Banmao Capsules combined with Oxaliplatin for injection in treatment of non-small cell lung cancer. Methods Patients(80 cases) with non-small cell lung cancer in Cangzhou Central Hospital from January 2015 to September 2017 were randomly divided into control(36 cases) and treatment(44 cases) groups. Patients in the control group were iv administered with Oxaliplatin for injection, 130 mg/m~2 added into 5% Glucose Solution 250 — 500 mL for 2 —6 h. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of control group, 3 grains/time, twice daily. A course of treatment had 3 weeks, and patients in two groups were treated for 6 courses. After treatment, the clinical effect was evaluated, and the KPS and adverse reactions in two groups before and after treatment were compared. Results After treatment, objective remission rates in the control and treatment groups were 33.33% and 56.82%, and the disease control rates were83.33% and 90.91%, respectively, but there were not statistically significant difference between two groups. After treatment, the KPS in the two groups were significantly increased(P < 0.05). And KPS in the treatment group were higher than that in the control group(P < 0.05). During the treatment, the number of patients with oral mucositis, abnormal liver and kidney function, and peripheral neurotoxicity in the control group were significantly higher than those in the treatment group, and there were differences between two groups(P < 0.05). Conclusion Compound Banmao Capsules combined with Oxaliplatin for injection has good clinical efficacy in the treatment of non-small cell lung cancer, can improve the quality of life of patients, and reduce adverse drug reactions, which has a certain clinical application value.
引文
[1]Spiro S G,Tanner N T,Silvestri G A,et al.Lung cancer:Progress in diagnosis,staging and therapy[J].Respirology,2010,15(1):44-50.
[2]Cho J H.Immunotherapy for non-small-cell lung cancer:current status and future obstacles[J].Immune Netw,2017,17(6):378-391.
[3]李改平,郭青云,朱贵荣,等.不同铂类物质对晚期非小细胞肺癌患者的临床疗效观察[J].实用癌症杂志,2016,31(11):1875-1877.
[4]段秋立.复方斑蝥胶囊治疗非小细胞肺癌的疗效观察[J].中药药理与临床,2016,32(1):191-192.
[5]李陶,刘雁冰,戢杨,等.复方斑蝥胶囊在中晚期非小细胞肺癌维持治疗中的应用[J].中国医药,2014,9(10):1455-1457.
[6]周纪昌.实用肿瘤内科学[M].第2版.北京:人民卫生出版社,2006:28-41.
[7]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[8]郑莹,王杰军,邹建军,等.上海市社区癌症患者生活质量及其影响因素[J].癌症,2007,26(6):613-619.
[9]黄金龙.非小细胞肺癌病因及治疗新进展[J].大理大学学报,2009,8(6):76-79.
[10]王绿化.局部晚期非小细胞肺癌的治疗进展[J].临床肿瘤学杂志,2006,11(5):321-325.
[11]彭全升,庞金凤,袁彬.复方斑蝥胶囊联合α1胸腺肽在晚期非小细胞肺癌维持治疗中的应用[J].中国美容医学杂志,2012,21(10):333-334.
[2]Cho J H.Immunotherapy for non-small-cell lung cancer:current status and future obstacles[J].Immune Netw,2017,17(6):378-391.
[3]李改平,郭青云,朱贵荣,等.不同铂类物质对晚期非小细胞肺癌患者的临床疗效观察[J].实用癌症杂志,2016,31(11):1875-1877.
[4]段秋立.复方斑蝥胶囊治疗非小细胞肺癌的疗效观察[J].中药药理与临床,2016,32(1):191-192.
[5]李陶,刘雁冰,戢杨,等.复方斑蝥胶囊在中晚期非小细胞肺癌维持治疗中的应用[J].中国医药,2014,9(10):1455-1457.
[6]周纪昌.实用肿瘤内科学[M].第2版.北京:人民卫生出版社,2006:28-41.
[7]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[8]郑莹,王杰军,邹建军,等.上海市社区癌症患者生活质量及其影响因素[J].癌症,2007,26(6):613-619.
[9]黄金龙.非小细胞肺癌病因及治疗新进展[J].大理大学学报,2009,8(6):76-79.
[10]王绿化.局部晚期非小细胞肺癌的治疗进展[J].临床肿瘤学杂志,2006,11(5):321-325.
[11]彭全升,庞金凤,袁彬.复方斑蝥胶囊联合α1胸腺肽在晚期非小细胞肺癌维持治疗中的应用[J].中国美容医学杂志,2012,21(10):333-334.